Platelet counts and hemoglobin values before and during therapy with thalidomide in 5 responding patients with AML.

Data represent individual values within a period of 20 days before and during treatment with thalidomide, the latter period independent of transfusion effects (■, patient no. 1; ▵, patient no. 3; ▿, patient no. 5; ⋄, patient no. 11; ○, patient no. 20). Closed symbols denote the values obtained on the day when thalidomide was started (day 0). (A) Median platelet counts were significantly higher during thalidomide treatment (day +1 to +45) compared with the pretreatment period (day −20 until day 0) (P = .042, Wilcoxon matched-pair signed rank test). (B) Hemoglobin values were not significantly different between the two time periods (P = .893).